InterveXion reports phase II data on IXT-m200 in methamphetamine use disorder April 20, 2021 No Comments
First subjects dosed in study comparing nasal nalmefene with nasal naloxone April 6, 2021 No Comments
Primary safety endpoint met in phase Ib/II study of BXCL-501 to treat opioid withdrawal symptoms April 1, 2021 No Comments
Neuron-specific delivery platform based on a chimeric toxin for botulism postexposure treatment Jan. 26, 2021 No Comments